FDA converts tarlatamab’s accelerated approval to full approval for small cell lung cancer, on a real survival benefit

High-Certainty EvidenceFDA-approved for the exact stated cancer/useNot addressed

The FDA granted full (traditional) approval to tarlatamab-dlle (Imdelltra), a DLL3xCD3 bispecific T-cell-engaging antibody, for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease progressed on or after platinum-based chemotherapy — converting the drug’s original May 2024 accelerated approval into a full approval on the strength of a randomized, confirmatory trial. The conversion was supported by the randomized, open-label, phase 3 DeLLphi-304 trial (ClinicalTrials.gov NCT05740566), which enrolled 509 patients with ES-SCLC who had progressed on platinum-based chemotherapy (with or without an anti-PD-(L)1 agent). Overall survival — the trial’s primary endpoint — was significantly longer with tarlatamab: median 13.6 months versus 8.3 months with standard-of-care chemotherapy (hazard ratio 0.60, P<.001), a real, statistically significant survival benefit. Tarlatamab works by simultaneously binding DLL3 (a protein expressed on small cell lung cancer cells) and CD3 on the patient's own T-cells, directing those T-cells to attack the cancer.

What This Means

In the randomized, open-label, phase 3 DeLLphi-304 trial, tarlatamab significantly extended overall survival compared with chemotherapy in patients with extensive-stage small cell lung cancer that had progressed after platinum-based chemotherapy -- median 13.6 months versus 8.3 months (hazard ratio 0.60, P<.001) -- a real, statistically significant survival benefit that converted the drug's original 2024 accelerated approval into a full, traditional FDA approval.

What This Doesn't Mean

This approval is specifically for patients whose disease has already progressed after platinum-based chemotherapy -- it is not a first-line small cell lung cancer treatment. This record relies on the ClinicalTrials.gov trial registry as its primary, verifiable source because a specific peer-reviewed publication's PMID/DOI for the DeLLphi-304 primary results was not located with confidence in this WebSearch-only pass -- a real, disclosed limitation, not a claim this trial has not been published.

Why It Matters

A statistically significant overall-survival benefit in a randomized, confirmatory phase 3 trial, converting an accelerated approval to full approval, represents real, mature, high-confidence evidence for a cancer type -- small cell lung cancer -- with historically very limited options once chemotherapy stops working.

Promise & Proof

Proof — strength of the evidence 5 / 5

Base score from evidence stage: High-Certainty Evidence.
FDA-approved for the exact stated cancer/use.

Promise — potential significance if later evidence holds up 3 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.
Targets a cancer type with historically limited effective treatment options.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy (with or without an anti-PD-(L)1 agent), randomized to tarlatamab or investigator's choice of chemotherapy, in the phase 3 DeLLphi-304 trial. (Adults)

A bispecific T-cell engager carries known risks including cytokine release syndrome, requiring specialized monitoring particularly around the first doses -- this record does not itself detail the full safety profile and that should be added before publication.

Full evidence details

Study design: Randomized controlled trial
Sample size: 509

Funding & Conflicts

Sponsor/developer: Amgen Inc. -- not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

United States (FDA)

Status: FDA-approved for the exact stated cancer/use
Indication: Adults with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy.
Biomarker requirement: DLL3-expressing small cell lung cancer (target of the bispecific antibody; not a patient-selection biomarker test)
Decision date: 2025-11-19
Source: Regulator record (opens in a new tab)

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

DeLLphi-304 trial registry (opens in a new tab) (Clinical-trial registry) NCT05740566 Load-bearing source NCT05740566
DeLLphi-304 trial registry. NCT05740566.

Why Should I Trust This?

1 source at Tier 1 — Government/regulatory authority (FDA, NCI, NIH, ClinicalTrials.gov, CDC, and equivalent)
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13